MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dogra, S. C.
Right arrow Articles by May, B. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dogra, S. C.
Right arrow Articles by May, B. K.

Vol. 63, Issue 1, 73-80, January 2003

Evidence That the Coactivator CBP/p300 Is Important for Phenobarbital-Induced but Not Basal Expression of the CYP2H1 Gene

Satish C. Dogra, David Tremethick, and Brian K. May

Department of Molecular Biosciences, Discipline of Biochemistry, the University of Adelaide, Adelaide, Australia (S.C.D., B.K.M.); and Chromatin and Transcriptional Regulation Group, the John Curtin School of Medical Research, Australian National University, Canberra, Australia (D.T.)

We have previously identified an upstream 556-bp enhancer domain for the chicken CYP2H1 gene that responds to phenobarbital and binds several transcription factors, including the orphan chicken xenobiotic receptor (CXR). By contrast, the promoter lacks a CXR site and is not inducible by phenobarbital. Although it has been established that CXR can interact with the coactivator SRC-1, there are no reports as to whether other coactivators may be important for phenobarbital-mediated inducibility. Our studies using the adenovirus E1A wild-type protein, which inhibits the coactivators cAMP response element binding protein (CBP) and CBP associated factor (p/CAF), provide evidence for the involvement of one or both of these coactivators at the enhancer but not at the promoter of the CYP2H1 gene. The observations that mutant E1A proteins did not affect the enhancer activity and that inhibition by wild-type E1A was reversed by CBP and p/CAF confirmed the involvement of these coactivators in the induction process. We propose that the intrinsic histone acetyl transferase activity of one or both of these coactivators participates in chromatin remodeling thereby stimulating drug induction of the promoter. This proposal was supported by experiments with the histone deacetylase inhibitor, trichostatin A, which resulted in the superinduction of the drug response but had little effect on basal expression of the CYP2H1 gene. The work provides evidence for the first time for the involvement of the coactivators CBP and p/CAF in the phenobarbital-mediated induction of the CYP2H1 gene.


Copyright © 2003 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Mol. Endocrinol.Home page
K. Swales and M. Negishi
CAR, Driving into the Future
Mol. Endocrinol., July 1, 2004; 18(7): 1589 - 1598.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
C. Handschin and U. A. Meyer
Induction of Drug Metabolism: The Role of Nuclear Receptors
Pharmacol. Rev., December 1, 2003; 55(4): 649 - 673.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics